Vizioli, G.; Nicoletti, A.; Feliciani, D.; Funaro, B.; Zileri Dal Verme, L.; Ponziani, F.R.; Zocco, M.A.; Gasbarrini, A.; Gabrielli, M.
Immunotherapy and MASLD-Related HCC: Should We Reconsider the Role of Etiology in the Therapeutic Approach to HCC? Appl. Sci. 2025, 15, 2279.
https://doi.org/10.3390/app15052279
AMA Style
Vizioli G, Nicoletti A, Feliciani D, Funaro B, Zileri Dal Verme L, Ponziani FR, Zocco MA, Gasbarrini A, Gabrielli M.
Immunotherapy and MASLD-Related HCC: Should We Reconsider the Role of Etiology in the Therapeutic Approach to HCC? Applied Sciences. 2025; 15(5):2279.
https://doi.org/10.3390/app15052279
Chicago/Turabian Style
Vizioli, Giuseppina, Alberto Nicoletti, Daniela Feliciani, Barbara Funaro, Lorenzo Zileri Dal Verme, Francesca Romana Ponziani, Maria Assunta Zocco, Antonio Gasbarrini, and Maurizio Gabrielli.
2025. "Immunotherapy and MASLD-Related HCC: Should We Reconsider the Role of Etiology in the Therapeutic Approach to HCC?" Applied Sciences 15, no. 5: 2279.
https://doi.org/10.3390/app15052279
APA Style
Vizioli, G., Nicoletti, A., Feliciani, D., Funaro, B., Zileri Dal Verme, L., Ponziani, F. R., Zocco, M. A., Gasbarrini, A., & Gabrielli, M.
(2025). Immunotherapy and MASLD-Related HCC: Should We Reconsider the Role of Etiology in the Therapeutic Approach to HCC? Applied Sciences, 15(5), 2279.
https://doi.org/10.3390/app15052279
